Targeting PI3 kinase in cancer

Pharmacology and Therapeutics

Volumn 146, Issue , 2015, Pages 53-60

  Bauer, Todd M ^a,b   Patel, Manish R ^a,c   Infante, Jeffrey R ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Florida Cancer Specialists   (United States)

Author keywords

Isoforms; PI3K inhibitors; PI3K pathway; PI3K Akt mTOR; Review

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ARTICLE; DIARRHEA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; NAUSEA; PRIORITY JOURNAL; RASH; SIGNAL TRANSDUCTION; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84921260783     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.09.006Associateeditor:S.J.Enna     Document Type: Article

References (89)

1. I.U. Ali, L.M. Schriml, and M. Dean Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity J Natl Cancer Inst 91 1999 1922 1932
2. D.A. Altomare, L. Zhang, J. Deng, A. Di Cristofano, A.J. Klein-Szanto, R. Kumar, and J.R. Testa GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt Clin Cancer Res 16 2010 486 496
3. H.-T. Arkenau, S.F. Jones, C. Kurkjian, J.R. Infante, S. Pant, H.A. Burris, K.N. Moore, D.S. McMeekin, F.A. Greco, S. Ramsey, and J.C. Bendell The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors ASCO Meeting Abstracts 30 2012 3097
4. U. Banerji, E.J. Dean, M. Gonzalez, A.P. Greystoke, B. Basu, M. Krebs, M. Puglisi, L. Grinsted, E. Oelmann, W. Burke, E. Harrington, S. Green, and M. Ranson First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors ASCO Meeting Abstracts 30 2012 3004
5. J. Baselga, M. Campone, M. Piccart, H.A. Burris III, H.S. Rugo, T. Sahmoud, S. Noguchi, M. Gnant, K.I. Pritchard, F. Lebrun, J.T. Beck, Y. Ito, D. Yardley, I. Deleu, A. Perez, T. Bachelot, L. Vittori, Z. Xu, P. Mukhopadhyay, D. Lebwohl, and G.N. Hortobagyi Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
6. S. Bauer, L.K. Yu, G.D. Demetri, and J.A. Fletcher Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor Cancer Res 66 2006 9153 9161
7. J.C. Bendell, J. Rodon, H.A. Burris, M. de Jonge, J. Verweij, D. Birle, D. Demanse, S.S. De Buck, Q.C. Ru, M. Peters, M. Goldbrunner, and J. Baselga Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors J Clin Oncol 30 2012 282 290
8. D.M. Benson, B.S. Kahl, R.R. Furman, J.R. Brown, N.D. Wagner-Johnston, S.E. Coutre, S.E.F. Spurgeon, J.C. Byrd, J. Leonard, S. Peterman, D.M. Johnson, Y. Cho, R.D. Dansey, W.R. Godfrey, and I. Flinn Final results of a phase I study of idelalisib, a selective inhibitor of PI3K{delta}, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL) ASCO Meeting Abstracts 31 2013 8526
9. I. Brana, P. LoRusso, J. Baselga, E.I. Heath, A. Patnaik, S. Gendreau, A. Laird, and K. Papadopoulos A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies ASCO Meeting Abstracts 28 2010 3030
10. J.R. Brown, R.R. Furman, I. Flinn, S.E. Coutre, N.D. Wagner-Johnston, B.S. Kahl, S.E.F. Spurgeon, D.M. Benson, S. Peterman, D.M. Johnson, D. Li, R.D. Dansey, T.M. Jahn, and J.C. Byrd Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3K{delta}, in patients with relapsed or refractory CLL ASCO Meeting Abstracts 31 2013 7003
11. H. Burris, J. Rodon, S. Sharma, R.S. Herbst, J. Tabernero, J.R. Infante, A. Silva, D. Demanse, W. Hackl, and J. Baselga First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors ASCO Meeting Abstracts 28 2010 3005
12. M. Cheung, and J.R. Testa Diverse mechanisms of AKT pathway activation in human malignancy Curr Cancer Drug Targets 13 2013 234 244
13. L.M. Chow, and S.J. Baker PTEN function in normal and neoplastic growth Cancer Lett 241 2006 184 196
14. S.E. Coutre, J.P. Leonard, R.R. Furman, J.C. Barrientos, S. de Vos, I.W. Flinn, M.T. Schreeder, N.D. Wagner-Johnston, J. Sharman, T.E. Boyd, N.H. Fowler, L.M. Holes, B.J. Lannutti, D.M. Johnson, L.L. Miller, and T.M. Jahn Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (CAL-101) with Rituximab and/or Bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): results from a phase I study ASH annual meeting abstracts 120 2012 191
15. B.R. Davies, H. Greenwood, P. Dudley, C. Crafter, D.H. Yu, J. Zhang, J. Li, B. Gao, Q. Ji, J. Maynard, S.A. Ricketts, D. Cross, S. Cosulich, C.C. Chresta, K. Page, J. Yates, C. Lane, R. Watson, R. Luke, D. Ogilvie, and M. Pass Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background Mol Cancer Ther 11 2012 873 887
16. S. De Vos, L.H. Sehn, S.P. Mulligan, M.H. Dreyling, M.J. Rummel, P.L. Zinzani, D.M. Johnson, S. Evans, R.D. Dansey, W.R. Godfrey, and M.S. Czuczman A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL) ASCO Meeting Abstracts 31 2013 TPS8618
17. J.A. Deane, and D.A. Fruman Phosphoinositide 3-kinase: diverse roles in immune cell activation Annu Rev Immunol 22 2004 563 598
18. G. Edelman, C. Bedell, G. Shapiro, S.S. Pandya, E.L. Kwak, C. Scheffold, L.T. Nguyen, A. Laird, J. Baselga, and J. Rodon A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies ASCO Meeting Abstracts 28 2010 3004
19. S.L. Ellard, M. Clemons, K.A. Gelmon, B. Norris, H. Kennecke, S. Chia, K. Pritchard, A. Eisen, T. Vandenberg, M. Taylor, E. Sauerbrei, M. Mishaeli, D. Huntsman, W. Walsh, M. Olivo, L. McIntosh, and L. Seymour Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163 J Clin Oncol 27 2009 4536 4541
20. J.A. Engelman, J. Luo, and L.C. Cantley The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev Genet 7 2006 606 619
21. H.A. Eradat, S.E. Coutre, J.C. Barrientos, K.R. Rai, C.M. Farber, P. Hillmen, J.P. Sharman, P. Ghia, B. Coiffier, J.A. Walewski, Z.N. Berneman, S.M. O'Brien, J.R. Brown, S. Peterman, R.D. Dansey, T.M. Jahn, P. Cramer, and M.J. Hallek A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL) ASCO Meeting Abstracts 31 2013 TPS7133
22. I. Flinn, E. Kimby, F.E. Cotter, F.J. Giles, A. Janssens, E.J. Pulczynski, L. Ysebeart, A. Pluta, J.A. Garcia Marco, K. Taylor, C. Owen, D.M. Johnson, M. Aiello, R.D. Dansey, R.L. Dubowy, and J.A. Jones A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL) ASCO Meeting Abstracts 31 2013 TPS7131
23. D.N. Franz, E. Belousova, S. Sparagana, E.M. Bebin, M. Frost, R. Kuperman, O. Witt, M.H. Kohrman, J.R. Flamini, J.Y. Wu, P. Curatolo, P.J. de Vries, V.H. Whittemore, E.A. Thiele, J.P. Ford, G. Shah, H. Cauwel, D. Lebwohl, T. Sahmoud, and S. Jozwiak Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial Lancet 381 2013 125 132
24. D.A. Fruman Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes Biochem Soc Trans 32 2004 315 319
25. W.P. Fung-Leung Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and function Cell Signal 23 2011 603 608
26. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, S. Begum, N.Q. McDonald, A. Butler, D. Jones, K. Raine, C. Latimer, C.R. Santos, M. Nohadani, A.C. Eklund, B. Spencer-Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P.A. Futreal, and C. Swanton Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
27. A.M. Gonzalez-Angulo, D. Juric, G. Argiles, J.H. Schellens, H.A. Burris, J. Berlin, M.R. Middleton, M.H. Schuler, R.V. Geel, T. Helgason, D. Bootle, M. Boehm, T.K. Goggin, D. Demanse, C. Quadt, and J. Baselga Safety, pharmacokinetics, and preliminary activity of the {alpha}-specific PI3K inhibitor BYL719: results from the first-in-human study ASCO Meeting Abstracts 31 2013 2531
28. M. Hardt, N. Chantaravisoot, and F. Tamanoi Activating mutations of TOR (target of rapamycin) Genes Cells 16 2011 141 151
29. B.T. Hennessy, D.L. Smith, P.T. Ram, Y. Lu, and G.B. Mills Exploiting the PI3K/AKT pathway for cancer drug discovery Nat Rev Drug Discov 4 2005 988 1004
30. S.E.M. Herman, A.L. Gordon, A.J. Wagner, N.A. Heerema, W. Zhao, J.M. Flynn, J. Jones, L. Andritsos, K.D. Puri, B.J. Lannutti, N.A. Giese, X. Zhang, L. Wei, J.C. Byrd, and A.J. Johnson Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals Blood 116 2010 2078 2088
31. A. Hollebecque, A. Clamp, L. Horsley, J.A. Morgan, R. Bahleda, S. George, D. Shaw, J.O. Lauchle, J.A. Ware, R. Desai, J. Wu, L. Fu, G.C. Jayson, J.C. Soria, and A.J. Wagner A phase 1 study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW) 2011 American Association for Cancer Research Orlando, FL
32. D.S. Hong, D.W. Bowles, G.S. Falchook, W.A. Messersmith, G.C. George, C.L. O'Bryant, A.C.H. Vo, K. Klucher, R.S. Herbst, S.G. Eckhardt, S. Peterson, D.F. Hausman, R. Kurzrock, and A. Jimeno A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors Clin Cancer Res 18 2012 4173 4182
33. S.M. Horwitz, I. Flinn, M.R. Patel, A. Younes, F.M. Foss, Y. Oki, J. Sweeney, K. Allen, J. Dunbar, P.F. Kelly, and B.S. Kahl Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta},{gamma}, in patients with relapsed/refractory lymphoma ASCO Meeting Abstracts 31 2013 8518
34. J.H. Hsu, Y. Shi, P. Frost, H. Yan, B. Hoang, S. Sharma, J. Gera, and A. Lichtenstein Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways Oncogene 23 2004 3368 3375
35. G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovacevic, V. Lesovoy, I.G. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore, R.J. Motzer, and A.T. Global Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
36. N.T. Ihle, R. Williams, S. Chow, W. Chew, M.I. Berggren, G. Paine-Murrieta, D.J. Minion, R.J. Halter, P. Wipf, R. Abraham, L. Kirkpatrick, and G. Powis Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Mol Cancer Ther 3 2004 763 772
37. J.R. Infante, L. Gandhi, G. Shapiro, N. Rizvi, H.A. Burris, J.C. Bendell, J. Baselga, K. Hsu, O. von Richter, G. Locatelli, E. Asatiani, and R.S. Heist Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: results of a phase 1b dose-escalation trial 2013 American Association for Cancer Research Washington, DC
38. D. Juric, I.E. Krop, R.K. Ramanathan, J. Xiao, S. Sanabria, T.R. Wilson, Y.J. Choi, H. Parmar, J.Y. Hsu, J. Baselga, and D.D. Von Hoff GDC-0032, a beta isoform-sparing PI3K inhibitor: results of a first-in-human dose escalation study 2013 American Association for Cancer Research Washington, D.C.
39. D. Juric, J. Rodan, A.M. Gonzalez-Angulo, H. Burris III, J.C. Bendell, J.D. Berlin, M.R. Middleton, D. Bootle, M. Boehm, A. Schmitt, N. Rouyrre, C. Quadt, and J. Baselga BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research (Vol. Abstract number CT-01) 2012 Cancer Research Chicago, IL
40. S. Kang, A. Denley, B. Vanhaesebroeck, and P.K. Vogt Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase Proc Natl Acad Sci U S A 103 2006 1289 1294
41. R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, and M.D. Waterfield Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer Annu Rev Cell Dev Biol 17 2001 615 675
42. T. Kodaki, R. Woscholski, B. Hallberg, P. Rodriguez-Viciana, J. Downward, and P.J. Parker The activation of phosphatidylinositol 3-kinase by Ras Curr Biol 4 1994 798 806
43. B.J. Lannutti, S.A. Meadows, S.E.M. Herman, A. Kashishian, B. Steiner, A.J. Johnson, J.C. Byrd, J.W. Tyner, M.M. Loriaux, M. Deininger, B.J. Druker, K.D. Puri, R.G. Ulrich, and N.A. Giese CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 2011 591 594
44. T. Maehama, and J.E. Dixon The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate J Biol Chem 273 1998 13375 13378
45. S.M. Maira, S. Pecchi, A. Huang, M. Burger, M. Knapp, D. Sterker, C. Schnell, D. Guthy, T. Nagel, M. Wiesmann, S. Brachmann, C. Fritsch, M. Dorsch, P. Chene, K. Shoemaker, A. De Pover, D. Menezes, G. Martiny-Baron, D. Fabbro, C.J. Wilson, R. Schlegel, F. Hofmann, C. Garcia-Echeverria, W.R. Sellers, and C.F. Voliva Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor Mol Cancer Ther 11 2012 317 328
46. N. Miled, Y. Yan, W.C. Hon, O. Perisic, M. Zvelebil, Y. Inbar, D. Schneidman-Duhovny, H.J. Wolfson, J.M. Backer, and R.L. Williams Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit Science 317 2007 239 242
47. R. Millham, B. Houk, G. Borzillo, P. LoRusso, L. Marburg, C. Britten, Z. Wainberg, A.A. Adjei, and G. Dy First-in-patient study of PF-049691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: update on safety, efficacy, and pharmacology AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics (Vol. 10, pp. Abstr nr B163) 2011 Molecular Cancer Therapeutics San Francisco, CA
48. V. Moreno Garcia, R.D. Baird, K.J. Shah, B. Basu, N. Tunariu, M. Blanco, P.A. Cassier, J.V. Pedersen, M. Puglisi, D. Sarker, D. Papadatos-Pastos, A.G. Omlin, A. Biondo, J.A. Ware, H. Koeppen, G.G. Levy, K.E. Mazina, and J.S. De Bono A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma ASCO Meeting Abstracts 29 2011 3021
49. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, S. Bracarda, V. Grunwald, J.A. Thompson, R.A. Figlin, N. Hollaender, G. Urbanowitz, W.J. Berg, A. Kay, D. Lebwohl, A. Ravaud, and R.-S. Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
50. P.N. Munster, R. van der Noll, E.E. Voest, E.C. Dees, A.R. Tan, J.M. Specht, G.S. Falchook, A. Daud, M.P. Lolkema, J.E. Grilley-Olson, E.Y. Yu, S. Fu, E.K. Bergsland, J. Kleha, S. Peng, D.A. Smith, T.A. Lampkin, J.H.M. Schellens, S.R. Morris, and R. Kurzrock Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826) ASCO Meeting Abstracts 29 2011 3018
51. S.M. O'Brien, N. Lamanna, T.J. Kipps, I. Flinn, A.D. Zelenetz, J.A. Burger, L. Holes, D.M. Johnson, J. Gu, R.D. Dansey, R.L. Dubowy, and S.E. Coutre A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K{delta}) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) > =65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) ASCO Meeting Abstracts 31 2013 7005
52. A.G. Olivero, T.P. Heffron, M. Baumgardner, M. Belvin, L. Berry Ross, N. Blaquiere, E. Bradley, G. Castanedo, M.K. Derynck, S. Do, J. Dotson, D. Dudley, K. Edgar, A. Folkes, R. Francis, T. Gianetti, R. Goldsmith, P. Goldsmith, J. Guan, T. Harrison, R. Heald, J. Hsu, P. Jackson, G. Jones, A. Kim, A. Kolesnikov, M. Lackner, L. Lee, J. Lesnick, C. Lewis, M. Mamounas, N. McLean, J. Murray, C. Ndubaku, J. Nonomiya, J. Pang, N. Pegg, W.W. Prior, L. Salphati, D. Sampath, S. Sideris, M. Siu, S. Staben, D. Sutherlin, M. Ultsch, J. Wallin, L. Wang, C. Wiesman, X. Zhang, and L.S. Friedman Discovery of GDC-0032: a beta-sparing PI3K inhibitor active against PI3KCA mutant tumors 2013 American Association for Cancer Research Washington, DC
53. M.E. Pacold, S. Suire, O. Perisic, S. Lara-Gonzalez, C.T. Davis, E.H. Walker, P.T. Hawkins, L. Stephens, J.F. Eccleston, and R.L. Williams Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma Cell 103 2000 931 943
54. M.R. Patel, B.S. Kahl, S.M. Horwitz, A. Younes, F.M. Foss, Y. Oki, J. Sweeney, K. Allen, K. Faia, P.F. Kelly, and I. Flinn Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta},{gamma}, in patients with relapsed/refractory CLL ASCO Meeting Abstracts 31 2013 7070
55. C.G. Patel, M. Patel, A. Chakravarty, E.A. Gangolli, E. Barry, E.H. Westin, K. Jessen, S.D. Chitnis, J.R. Infante, M.S. Gordon, T. Macarulla, A. Cervantes-Ruiperez, S.I. Jalal, and K. Venkatakrishnan Clinical pharmacokinetics (PK) and translational PK-pharmacodynamic (PD) modeling and simulation to predict antitumor response of various dosing schedules to guide the selection of a recommended phase II dose (RP2D) and schedule for the investigational agent MLN0128 ASCO Meeting Abstracts 31 2013 2567
56. A. Patnaik, L.J. Appleman, J.M. Mountz, R.K. Ramanathan, M. Beeram, A.W. Tolcher, K.P. Papadopoulos, M.T. Lotze, D.P. Petro, C. Laymon, L. Paige, P. Rajagopalan, M. Jeffers, D. Roth, and R.L. Dubowy A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: results of dose-escalation phase ASCO Meeting Abstracts 29 2011 3035
57. A. Patnaik, R.K. Ramanathan, L.J. Appleman, A.W. Tolcher, J.M. Mountz, M. Beerham, G.J. Weiss, D.W. Rasco, M.T. Lotze, F.G.S. Toledo, M.J. Oborski, P. Rajagopalan, M. Jeffers, A. Kelly, and I. Genvresse Phase I study of intravenous PI3K inhibitor BAY 80-6946: preliminary activity in patients with relapsed non-Hodgkin lymphoma (NHL) treated in an expansion cohort 54th ASH Annual Meeting and Exposition (pp. Abst 3704). Atlanta, GA 2012
58. J.D. Peyton, J. Rodon Ahnert, H. Burris, C. Britten, L.C. Chen, J. Tabernero, V. Duval, N. Rouyrre, A.P. Silva, C. Quadt, and J. Baselga A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors ASCO Meeting Abstracts 29 2011 3066
59. J. Rodon, D. Juric, A.M. Gonzalez-Angulo, J.C. Bendell, J.D. Berlin, D. Bootle, K. Gravelin, A. Huang, A. Derti, J. Lehar, J. Wurthner, M. Boehm, E. van Allen, N. Wagle, L.A. Garraway, R. Yelensky, P.J. Stephens, V.A. Miller, R. Schlegel, C. Quadt, and J. Baselga Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor 2013 American Association for Cancer Research Washington, DC
60. P. Rodriguez-Viciana, P.H. Warne, R. Dhand, B. Vanhaesebroeck, I. Gout, M.J. Fry, M.D. Waterfield, and J. Downward Phosphatidylinositol-3-OH kinase as a direct target of Ras Nature 370 1994 527 532
61. T. Ruckle, M.K. Schwarz, and C. Rommel PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? Nat Rev Drug Discov 5 2006 903 918
62. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S.M. Powell, G.J. Riggins, J.K. Willson, S. Markowitz, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
63. D. Sarker, R. Kristeleit, K.E. Mazina, J.A. Ware, Y. Yan, M. Dresser, M.K. Derynck, and J. De-Bono A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941 ASCO Meeting Abstracts 27 2009 3538
64. S. Semba, N. Itoh, M. Ito, M. Harada, and M. Yamakawa The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells Clin Cancer Res 8 2002 1957 1963
65. G.I. Shapiro, G. Edelman, E. Calvo, S.K. Aggarwal, and A.D. Laird Targeting aberrant PI3K pathway signaling with XL147, a potent, selective, and orally bioavailable PI3K inhibitor Proc 97th Annu Meet AACR (Vol. Abstract C205). Los Angeles, CA 2007
66. R.J. Shaw, and L.C. Cantley Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature 441 2006 424 430
67. A.T. Shaw, D.W. Kim, K. Nakagawa, T. Seto, L. Crino, M.J. Ahn, T. De Pas, B. Besse, B.J. Solomon, F. Blackhall, Y.L. Wu, M. Thomas, K.J. O'Byrne, D. Moro-Sibilot, D.R. Camidge, T. Mok, V. Hirsh, G.J. Riely, S. Iyer, V. Tassell, A. Polli, K.D. Wilner, and P.A. Janne Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
68. K.C. Shih, J.C. Bendell, A. Reinert, S. Jones, R.K. Kelley, J.R. Infante, M. Korn, K. Hege, R. Chopra, S. Xu, L. Wong, Y. Liu, D. Mortensen, and P.N. Munster Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers ASCO Meeting Abstracts 30 2012 3006
69. E.Y. Skolnik, B. Margolis, M. Mohammadi, E. Lowenstein, R. Fischer, A. Drepps, A. Ullrich, and J. Schlessinger Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases Cell 65 1991 83 90
70. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, J.S. Weber, G.A. McArthur, T.E. Hutson, S.J. Moschos, K.T. Flaherty, P. Hersey, R. Kefford, D. Lawrence, I. Puzanov, K.D. Lewis, R.K. Amaravadi, B. Chmielowski, H.J. Lawrence, Y. Shyr, F. Ye, J. Li, K.B. Nolop, R.J. Lee, A.K. Joe, and A. Ribas Survival in BRAF V600-mutant advanced melanoma treated with Vemurafenib N Engl J Med 366 2012 707 714
71. S.E.F. Spurgeon, N.D. Wagner-Johnston, R.R. Furman, I. Flinn, S.E. Coutre, J.R. Brown, D.M. Benson, J.C. Byrd, J. Leonard, S. Peterman, D.M. Johnson, J. Gu, R.D. Dansey, W.R. Godfrey, and B.S. Kahl Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110{delta} (PI3K{delta}), in patients with relapsed or refractory mantle cell lymphoma (MCL) ASCO Meeting Abstracts 31 2013 8519
72. T.W. Sturgill, and M.N. Hall Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCα ACS Chem Biol 4 2009 999 1015
73. S. Suire, P. Hawkins, and L. Stephens Activation of phosphoinositide 3-kinase gamma by Ras Curr Biol 12 2002 1068 1075
74. D.P. Sutherlin, L. Bao, M. Berry, G. Castanedo, I. Chuckowree, J. Dotson, A. Folks, L. Friedman, R. Goldsmith, J. Gunzner, T. Heffron, J. Lesnick, C. Lewis, S. Mathieu, J. Murray, J. Nonomiya, J. Pang, N. Pegg, W.W. Prior, L. Rouge, L. Salphati, D. Sampath, Q. Tian, V. Tsui, N.C. Wan, S. Wang, B. Wei, C. Wiesmann, P. Wu, B.Y. Zhu, and A. Olivero Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer J Med Chem 54 2011 7579 7587
75. A. Suzuki, T. Nakano, T.W. Mak, and T. Sasaki Portrait of PTEN: messages from mutant mice Cancer Sci 99 2008 209 213
76. C. Swanton Intratumor heterogeneity: evolution through space and time Cancer Res 72 2012 4875 4882
77. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A.T. van Oosterom, M.C. Christian, and S.G. Gwyther New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
78. B. Vanhaesebroeck, K. Ali, A. Bilancio, B. Geering, and L.C. Foukas Signalling by PI3K isoforms: insights from gene-targeted mice Trends Biochem Sci 30 2005 194 204
79. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 2002 489 501
80. N.D. Wagner-Johnston, S. De Vos, J. Leonard, J.P. Sharman, M.T. Schreeder, R.V. Boccia, J.C. Barrientos, S.E. Coutre, I. Flinn, T.E. Boyd, L. Holes, D.M. Johnson, Y. Kim, R.D. Dansey, W.R. Godfrey, and N.H. Fowler Preliminary results of PI3K{delta} inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL) ASCO Meeting Abstracts 31 2013 8501
81. R. Wetzker, and C. Rommel Phosphoinositide 3-kinases as targets for therapeutic intervention Curr Pharm Des 10 2004 1915 1922
82. P. Wipf, and R.J. Halter Chemistry and biology of wortmannin Org Biomol Chem 3 2005 2053 2061
83. P. Wipf, D.J. Minion, R.J. Halter, M.I. Berggren, C.B. Ho, G.G. Chiang, L. Kirkpatrick, R. Abraham, and G. Powis Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin Org Biomol Chem 2 2004 1911 1920
84. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, E. Van Cutsem, T.J. Hobday, T. Okusaka, J. Capdevila, E.G.E. de Vries, P. Tomassetti, M.E. Pavel, S. Hoosen, T. Haas, J. Lincy, D. Lebwohl, and K. Öberg Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
85. T.A. Yap, L. Yan, A. Patnaik, I. Fearen, D. Olmos, K. Papadopoulos, R.D. Baird, L. Delgado, A. Taylor, L. Lupinacci, R. Riisnaes, L.L. Pope, S.P. Heaton, G. Thomas, M.D. Garrett, D.M. Sullivan, J.S. de Bono, and A.W. Tolcher First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors J Clin Oncol 29 2011 4688 4695
86. T.L. Yuan, and L.C. Cantley PI3K pathway alterations in cancer: variations on a theme Oncogene 27 2008 5497 5510
87. T.L. Yuan, G. Wulf, L. Burga, and L.C. Cantley Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations Curr Biol 21 2011 173 183
88. K.M. Zbuk, and C. Eng Cancer phenomics: RET and PTEN as illustrative models Nat Rev Cancer 7 2007 35 45
89. L. Zhao, and P.K. Vogt Class I PI3K in oncogenic cellular transformation Oncogene 27 2008 5486 5496